- VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q2 GAAP EPS of -$0.08.
- At September 30, 2022, the Company had cash and cash equivalents of approximately $35.3 million.
- "As a result of the conclusion of certain clinical trial activity and deferral of several research and development and pre-commercialization activities, the Company anticipates a decrease in spending over the next few quarters which the Company expects will extend its cash runway through a series of potential key milestones and data readouts in 2023," report.
For further details see:
VistaGen Therapeutics GAAP EPS of -$0.08